These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 897913)

  • 1. Prophyrin precursors in blood, urine and cerebrospinal fluid in acute porphyria.
    Percy VA; Shanley BC
    S Afr Med J; 1977 Jul; 52(6):219-22. PubMed ID: 897913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catecholamine uptake, accumulation, and release in acute porphyria.
    Beal MF; Atuk NO; Westfall TC; Turner SM
    J Clin Invest; 1977 Nov; 60(5):1141-8. PubMed ID: 908757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of acute porphyria.
    Yeung Laiwah AC; Moore MR; Goldberg A
    Q J Med; 1987 May; 63(241):377-92. PubMed ID: 3310073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herbicide-induced experimental variegate porphyria in mice: tissue porphyrinogen accumulation and response to porphyrogenic drugs.
    Krijt J; Stranska P; Maruna P; Vokurka M; Sanitrak J
    Can J Physiol Pharmacol; 1997; 75(10-11):1181-7. PubMed ID: 9431441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of neural manifestations in acute porphyria.
    Shanley BC; Percy VA; Neethling AC
    S Afr Med J; 1977 Apr; 51(14):458-60. PubMed ID: 870989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The porphyrias [corrected]: characteristics and laboratory tests.
    Ellefson RD; Ford RE
    Regul Toxicol Pharmacol; 1996 Aug; 24(1 Pt 2):S119-25. PubMed ID: 8921566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms.
    Mustajoki P; Timonen K; Gorchein A; Seppäläinen AM; Matikainen E; Tenhunen R
    Eur J Clin Invest; 1992 Jun; 22(6):407-11. PubMed ID: 1633836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
    Sardh E; Harper P; Andersson DE; Floderus Y
    Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Letter: Comments and conclusion to H. Stutzer: Typical and atypical roentgen pictures in the acute porphyria. Fortschr. Röntgenstr. 123,6 (1975) 588-590].
    Doss M; Stutzer H
    Rofo; 1976 Jul; 125(1):78-9. PubMed ID: 133951
    [No Abstract]   [Full Text] [Related]  

  • 10. Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria.
    Marsden JT; Rees DC
    J Clin Pathol; 2014 Jan; 67(1):60-5. PubMed ID: 23908454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. delta-Aminolaevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects.
    Gorchein A; Webber R
    Clin Sci (Lond); 1987 Jan; 72(1):103-12. PubMed ID: 3802715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.
    Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P
    Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of the porphyrin precursors delta-aminolaevulinic acid (ALA) and porphobilinogen (PBG) in the acute attack of porphyria.
    Kramer S; Becker D; Viljoen D
    S Afr Med J; 1973 Sep; 47(38):1735-8. PubMed ID: 4270402
    [No Abstract]   [Full Text] [Related]  

  • 14. Direct and simultaneous quantitation of 5-aminolaevulinic acid and porphobilinogen in human serum or plasma by hydrophilic interaction liquid chromatography-atmospheric pressure chemical ionization/tandem mass spectrometry.
    Benton CM; Couchman L; Marsden JT; Rees DC; Moniz C; Lim CK
    Biomed Chromatogr; 2013 Feb; 27(2):267-72. PubMed ID: 23180457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperinsulinemia in acute intermittent porphyria.
    Sixel-Dietrich F; Verspohl F; Doss M
    Horm Metab Res; 1985 Jul; 17(7):375-6. PubMed ID: 3897010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorbent therapy of the porphyrias. II. Experimental plasma or hemoperfusion with a commercial charcoal cartridge.
    Tishler PV; Gordon BJ
    Methods Find Exp Clin Pharmacol; 1983; 5(3):185-91. PubMed ID: 6888085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorbent therapy of the porphyrias. V. Adsorption of the porphyrin precursors delta-aminolevulinic acid and porphobilinogen by sorbents in vitro.
    Winston SH; Tishler PV
    Methods Find Exp Clin Pharmacol; 1986 Apr; 8(4):233-7. PubMed ID: 3724299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A LC-MS/MS method for the specific, sensitive, and simultaneous quantification of 5-aminolevulinic acid and porphobilinogen.
    Zhang J; Yasuda M; Desnick RJ; Balwani M; Bishop D; Yu C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(24):2389-96. PubMed ID: 21783436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorbent therapy of the porphyrias. III. Comparative efficacy of experimental plasma perfusion with several commercial hemoperfusion cartridges.
    Tishler PV; Winston SH
    Methods Find Exp Clin Pharmacol; 1984 Jul; 6(7):389-93. PubMed ID: 6503474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nephrologists and porphyrias].
    Canavese C; Gabrielli D; Guida C; Cappellini MD
    G Ital Nefrol; 2002; 19(4):393-412. PubMed ID: 12369042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.